Literature DB >> 20410528

Drug resistance, epigenetics, and tumor cell heterogeneity.

Timothy Hoey1.   

Abstract

The resistance of cancer cells to various therapeutic agents and modalities is a crucial issue in clinical oncology. A recent Cell paper highlights how changes at the chromatin level control drug sensitivity and provides insight into more effective strategies for treating cancer with combination therapies.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20410528     DOI： 10.1126/scitranslmed.3001056

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN： 1946-6234            Impact factor:   17.956


  14 in total

1.  Resistance, epigenetics and the cancer ecosystem.

Authors:  Stephen B Baylin
Journal:  Nat Med       Date:  2011-03       Impact factor: 53.440

Review 2.  Critical role of HMGA proteins in cancer cell chemoresistance.

Authors:  Daniela D'Angelo; Paula Mussnich; Claudio Arra; Sabrina Battista; Alfredo Fusco
Journal:  J Mol Med (Berl)       Date:  2017-03-14       Impact factor: 4.599

3.  Rational Design of a Parthenolide-based Drug Regimen That Selectively Eradicates Acute Myelogenous Leukemia Stem Cells.

Authors:  Shanshan Pei; Mohammad Minhajuddin; Angelo D'Alessandro; Travis Nemkov; Brett M Stevens; Biniam Adane; Nabilah Khan; Fred K Hagen; Vinod K Yadav; Subhajyoti De; John M Ashton; Kirk C Hansen; Jonathan A Gutman; Daniel A Pollyea; Peter A Crooks; Clayton Smith; Craig T Jordan
Journal:  J Biol Chem       Date:  2016-08-29       Impact factor: 5.157

4.  Three-dimensional mRNA measurements reveal minimal regional heterogeneity in esophageal squamous cell carcinoma.

Authors:  Wusheng Yan; Joanna Shih; Jaime Rodriguez-Canales; Michael A Tangrea; Audrey Player; Lixia Diao; Nan Hu; Alisa M Goldstein; Jing Wang; Philip R Taylor; Scott M Lippman; Ignacio I Wistuba; Michael R Emmert-Buck; Heidi S Erickson
Journal:  Am J Pathol       Date:  2012-12-03       Impact factor: 4.307

5.  Rapid optimization of drug combinations for the optimal angiostatic treatment of cancer.

Authors:  Andrea Weiss; Xianting Ding; Judy R van Beijnum; Ieong Wong; Tse J Wong; Robert H Berndsen; Olivier Dormond; Marchien Dallinga; Li Shen; Reinier O Schlingemann; Roberto Pili; Chih-Ming Ho; Paul J Dyson; Hubert van den Bergh; Arjan W Griffioen; Patrycja Nowak-Sliwinska
Journal:  Angiogenesis       Date:  2015-04-01       Impact factor: 9.596

6.  Prognostic implication of intratumoral metabolic heterogeneity in invasive ductal carcinoma of the breast.

Authors:  Seung Hyun Son; Do-Hoon Kim; Chae Moon Hong; Choon-Young Kim; Shin Young Jeong; Sang-Woo Lee; Jaetae Lee; Byeong-Cheol Ahn
Journal:  BMC Cancer       Date:  2014-08-12       Impact factor: 4.430

7.  Prognostic value of intratumoral metabolic heterogeneity on F-18 fluorodeoxyglucose positron emission tomography/computed tomography in locally advanced cervical cancer patients treated with concurrent chemoradiotherapy.

Authors:  Gun Oh Chong; Won Kee Lee; Shin Young Jeong; Shin-Hyung Park; Yoon Hee Lee; Sang-Woo Lee; Dae Gy Hong; Jae-Chul Kim; Yoon Soon Lee
Journal:  Oncotarget       Date:  2017-06-28

8.  Drug resistance and combating drug resistance in cancer.

Authors:  Xuan Wang; Haiyun Zhang; Xiaozhuo Chen
Journal:  Cancer Drug Resist       Date:  2019-06-19

Review 9.  Progress in aptamer-mediated drug delivery vehicles for cancer targeting and its implications in addressing chemotherapeutic challenges.

Authors:  Jie Zhu; He Huang; Shiwu Dong; Liang Ge; Yuan Zhang
Journal:  Theranostics       Date:  2014-07-13       Impact factor: 11.556

10.  Loss of Scribble Promotes Snail Translation through Translocation of HuR and Enhances Cancer Drug Resistance.

Authors:  Yi Zhou; Renxu Chang; Weiwei Ji; Na Wang; Meiyan Qi; Yi Xu; Jingyu Guo; Lixing Zhan
Journal:  J Biol Chem       Date:  2015-11-02       Impact factor: 5.157
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.